SPOTLIGHT -
Multiple Myeloma: Use of Bispecifics in Challenging Patient Populations
Before closing out their program on bispecifics in multiple myeloma, expert oncologists consider the value of these agents in more challenging patient populations.
The Evolving Role of Non-BCMA-Targeting Bispecifics in Multiple Myeloma
Following their review of non-BCMA-targeting bispecifics in multiple myeloma, panelists consider practical use of these agents and how they may fit into the real-world treatment paradigm.
Non-BCMA-Targeting Bispecifics in Multiple Myeloma: Cevostamab
A brief discussion on clinical trial data with cevostamab therapy followed by considerations for other non-BCMA-targeted agents being studied in the setting of multiple myeloma.
Non-BCMA-Targeting Bispecifics in Multiple Myeloma: Talquetamab
Switching its focus to non-BCMA-targeting therapies, a panel of experts consider the clinical data behind talquetamab in patients diagnosed with multiple myeloma,
BCMA-Targeting Bispecifics in Multiple Myeloma: Safety Profile
Expert oncologists briefly review safety profiles of BCMA-targeted bispecifics in multiple myeloma and share practical insight on how to mitigate or address toxicities.
Multiple Myeloma: Selecting Among the BCMA-Targeting Therapies
Shared insight on how experts select among the available BCMA-targeting bispecific antibodies and CAR T-cell therapies in patients with multiple myeloma.
The Evolving Role of BCMA-Targeting Bispecifics in Multiple Myeloma
Expert panelists reflect on other clinical trials aimed at defining the role for BCMA-targeting bispecifics in multiple myeloma and consider how they would utilize this class of agents in real-world practice.
BCMA-Targeting Bispecifics in Multiple Myeloma: Teclistamab
Opening its discussion on BCMA-targeting bispecific antibodies in multiple myeloma, a panel of expert oncologists highlights key clinical data behind teclistamab.
Clinical Pearls and Unmet Needs in R/R Multiple Myeloma
Joshua Richter, MD, offers advice to community oncologists and discusses unmet needs in the treatment of patients with relapsed/refractory MM.
Bispecific Antibodies in the Treatment of Multiple Myeloma
An expert oncologist evaluates the effect of combination trials of bispecific antibodies on the multiple myeloma treatment landscape.
Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple-Class Refractory MM
An overview of recent data on selinexor, carfilzomib, and dexamethasone in triple-class refractory multiple myeloma, and treatment options to replace belantamab.
Role of Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Expert oncologist Joshua Richter, MD, defines triple-class refractory multiple myeloma and describes selinexor’s unique mechanism of action.
Overview of Multiple Myeloma and Treatment Options
Joshua Richter, MD, gives an overview of treatment options in multiple myeloma and factors that influence treatment decisions.
Multiple Myeloma Management: Addressing Disparities in Care
Before closing out their review on the management of multiple myeloma, panelists consider disparities in care and share how these barriers are being addressed.
Future Directions: Novel Targeted Therapies in Multiple Myeloma
A comprehensive review of novel therapy being investigated in the setting of relapsed/refractory multiple myeloma to expand the bispecific antibody and CAR T-cell therapy armamentarium.
Practical Factors in Selecting Therapy for Relapsed/Refractory MM
Shared insight on key factors that determine the best selection of therapy in patients with relapsed/refractory multiple myeloma, with a focus on bispecific antibodies and CAR T-cell therapy.
Patient Case 3: A 65-Year-Old Woman With Relapsed Multiple Myeloma
After reviewing their third patient case, expert hematologist-oncologists highlight the treatment armamentarium for relapsed/refractory multiple myeloma.
Treating High-Risk Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Before closing out their module on transplant-ineligible newly diagnosed multiple myeloma, panelists reflect on best treatment practices in the setting of high-risk disease.
Transplant-Ineligible NDMM: Optimizing Selection and Duration of Therapy
Practical perspectives on the optimal selection of therapy for transplant-ineligible NDMM, followed by considerations for duration of therapy and dosing.
Induction Therapy Options for Patients With Transplant-Ineligible NDMM
Expert perspectives on cornerstone induction therapy regimens used in patients with transplant-ineligible newly diagnosed multiple myeloma.
Patient Case 2: A 79-Year-Old Woman With Transplant-Ineligible NDMM
Switching their attention to the transplant-ineligible setting of newly diagnosed multiple myeloma, panelists center discussion around their second patient case.
Post-Transplant Therapy in NDMM: Consolidation and Maintenance Therapy
Expert hematologist-oncologists consider the role of maintenance and consolidation following the completion of transplant in patients with newly diagnosed multiple myeloma.
What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?
A brief review of the role of transplant in patients with newly diagnosed multiple myeloma and how it can be best coupled with systemic treatment.
Induction Regimens in Transplant-Eligible NDMM: Clinical Trial Data
Comprehensive insight on mainstay induction therapy options for patients with transplant-eligible newly diagnosed multiple myeloma in the context of recent clinical studies.
Patient Case 1: A 54-Year-Old Woman With Transplant-Eligible NDMM
Opening their discussion on the first patient case, expert panelists review the management of transplant-eligible newly diagnosed multiple myeloma.
Looking Forward: Advice for Clinicians and Discussing Unmet Needs in the R/R MM Landscape
Dr. Joshua Richter and Dr. Peter Forsberg close their discission with thoughtful advice for clinicians regarding the current and future treatment of patients with R/R MM.
Practical Considerations for Reducing Risk and Providing Supportive Care
Insights on supportive care measures to minimize or counter common adverse effects for patients with R/R MM taking selinexor-based therapies
Dosing Strategies and Adverse Events in Patients Treated with Selinexor
Discourse centered around dosing strategies for selinexor-based therapies.
Key Trial Data Supporting the Use of Selinexor in Patients with R/R MM
Two subject matter experts discuss keystone trials supporting the use of Selinexor in patients with R/R MM, each with unique dosing structures and different selinexor-based combinations.
An Overview of Treatment Options Available for Patients with R/R MM
Opening their discussion on relapsed/refractory multiple myeloma, Joshua Richter, MD and Peter Forsberg, MD review options for treatment sequencing, initiating treatment, and the mechanism of action for selinexor.